Navigation Links
Lilly CEO: 'Are We Getting Our Money's Worth from Medical Innovation?'
Date:10/29/2010

DALLAS, Oct. 29 /PRNewswire/ -- In a speech to the Dallas Friday Group today, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY), said that the value of medical innovation – particularly innovative medicines – far outstrips its cost.  Lechleiter marshaled data showing that medical innovation over the past century dramatically extended life spans, improved quality of life, and boosted productivity.

So far, the health care debate has revolved around access, quality, and cost—all of which need to be addressed, according to Lechleiter.  "But, we'll never improve in any of these areas – in fact, we risk going backwards – without taking into account two fundamental game-changers:  innovation and value."

By tackling diseases that had been impervious to medicine throughout human history, for example, medical innovation helped life expectancy rise by more than 30 years in the 20th century – an unprecedented 66 percent increase in life.  Thanks to medical technology – including innovative medicines, since 1975, Americans' death from heart disease has declined by nearly 60 percent, and five-year survival rates for cancer have expanded from 50 percent to nearly 70 percent.

"More than one million additional Americans would die of heart disease or stroke each year if the death rates were what they were 30 years ago," Lechleiter said, "and over 100,000 more people would be dying from cancer every year."

Lechleiter cited two economists who calculated that increasing life spans alone was worth as much as half the national GDP between 1970 and 1998.  Furthermore, medical innovation has also helped drive down the rates of functional disability, meaning people were living not just longer, but also better.

Lechleiter singled out innovative medicines as providing
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ADMD), ... the development of brachytherapy devices and medical isotopes ... a Life Sciences Discovery Fund (LSDF) Proof of ... is the commercialization partner.  The award was made ... titled "Optimized Injectable Radiogels for High-dose Therapy of ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... that Induction Chemotherapy prior to ChemoRadiotherapy significantly ... ChemoRadiotherapy alone -MADRID, May 30 The ... (TTCC) announced today that Induction Chemotherapy (IC) ... treatment paradigm defined as sequential therapy, compared ...
... Fla. , May 29 GlaxoSmithKline [NYSE: ... that the United States Food and Drug Administration,s ... to three that the ARZERRA(TM) (ofatumumab) data are ... with chronic lymphocytic leukemia (CLL) whose disease is ...
Cached Medicine Technology:Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... 7,178 small business owners and marketing professionals avoided ... opted instead to join Digital Marketer, an Austin, Texas ... annual “Black Friday Boot Camp”. , ... 5 hour online training event and raised $50,000 in ... Central Texas based charities dedicated to fighting childhood cancer. ...
(Date:12/22/2014)... 2014 NAPW honors ... of the Year. Ms. Foley is recognized with this ... most-recognized networking organization of professional women in the country, ... of Professional Women is a powerfully vibrant networking community ... , “As a nurse, I felt like I made ...
(Date:12/22/2014)... December 22, 2014 At the ... next month in San Antonio, esteemed experts ... dynamics that often stand in the way of ... , This premier faculty development opportunity is ... Leadership, whose mission is to assist nurse educators ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3
... May 28 In a world of internet savvy,patients ... scheduling,are readily available online. With a few clicks of ... friends and family and even buy,groceries! A patient,s experience ... be equally as user friendly., With the new ...
... mean development of new class of drugs, researchers say ... that inhibits HIV protease has been developed by researchers at ... necessary for HIV replication, is a common target in the ... HIV protease inhibitor compound to be developed in 20 years ...
... lead to more effective drugs to slow progression of ... gene that plays a role in Alzheimer,s disease in ... the neurodegenerative condition has been identified by U.S. researchers. ... 20 -- opens a new line of research that ...
... creases, saggy areas around the mouth and neck the ... are not inevitable. They result from a structural breakdown inside ... the growth of new, youthful collagen, University of Michigan scientists ... collagen collapse and possible renewal, based on more than a ...
... the University of Pennsylvania School of Medicine have shown ... decoy, receptor, binding growth factors that promote the progression ... lead to new drug designs for inhibiting cancer. The ... publication. , Many types of tumors grow because of ...
... athletes and non-athletes suffer from one or more components ... conditions that can lead to cardiovascular disease, according to ... in Milwaukee. , The study results were presented today ... by Anne Z. Hoch, D.O., associate professor of orthopedic ...
Cached Medicine News:Health News:Empowering Your Patients: Smile Dash Portal 'Bridges Gap' Between Dentists and Patients 2Health News:New Compound Slows HIV Replication 2Health News:Study IDs Gene for Late-Onset Alzheimer's 2Health News:Why some treatments rescue aging skin 2Health News:Why some treatments rescue aging skin 3Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:New study shows sedentary high school girls are at significant risk for future osteoporosis 2
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
Medicine Products: